Docetaxel

Conclusion: the combination of gefitinib and docetaxel at 60 mg m2 is tolerable, with interim results showing a median survival time of 4 mo this point. 20% and 30% versus 21%, respectively ; , yet within previously reported ranges [53, 54]. The mean n 12 ; docetaxel plasma concentrationtime curves for the two treatments illustrate the similarity between the two treatments Fig. 2. A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and or. Sayfa 7. Survival in favour of the patients treated with docetaxel. Although not part of the remit of the present study, one possible explanation could be that a greater number of patients treated with docetaxel had been transferred out of the study due to toxicity and proceeded to receive other lines of treatment such as irinotecan. The majority of the clinical and demographic characteristics of the patients entered into the present study are similar in both treatment groups and, as such, do not appear to be responsible for differences in the results obtained Table 1 ; . It needs to be highlighted that all of the patients who achieved an objective response had a histology diagnosis of adenocarcinoma and, furthermore, all except one had disease progression with the previous platinum therapy. The fact that the paclitaxel treatment group had a tendency towards a greater number of patients with adenocarcinoma could also have had an influence on the number of objective responses observed. With respect to toxicity, attention needs to be drawn to the pattern and distribution of the toxicities observed. Following a median of 6 weeks of the weekly schedule of treatment in both groups, it was of note that haematological toxicities were reduced compared with other administration schedules. Although this was slightly higher in the paclitaxel treatment group especially in the red blood cells ; , a possible influence of the previous platinum therapy's toxicity can be discarded. Conversely, the non-haematological toxicities, although not causing any toxic deaths, were significantly higher in the docetaxel treatment arm. This is seen clearly in the higher percentage of patients with mucosal toxicities diarrhoea stomatitis ; and, especially, the pulmonary toxicity. The tax-327 trial compared docetaxel 75mg m2 every three weeks or 30mg m2 weekly, five weeks of six ; with mitoxantrone. V Vadhan-Raj S, see Glaspy J Vahdat L, see Oktay K see Sparano JA Vahdat LT, see Herbst RS Vajtai I, see Mariani L Valagussa P, see Kaufmann M Valdimarsdottir HB, see Madalinska JB Valentine E, see Robert N Valero V, see Bruera E see Esmaeli B see Guarneri V see Hanrahan EO see Hess KR Valone FH, see Small EJ Valteau-Couanet D, see Rubie H Valverde M, see Fernandez-Aviles F van Apeldoorn MJ, Rustemeijer C, Voerman BJ, Peterse J. Mesothelioma of the Tunica Vaginalis Complicated by Chyluria, 5329 van Asperen CJ, see van Dijk S van Beurden M, see Madalinska JB van Boven-van Zomeren DM, see Loos WJ Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, Claus P, Mertens L, Lagae L, Delforge M, Paridaens R, Noens L, Humblet Y, Vandermeersch B, De Muylder X. In Utero Exposure to Chemotherapy: Effect on Cardiac and Neurologic Outcome correspondence ; , e16 Van Cutsem E, see Lenz H-J see Rojo F Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse M-L, Ajani JA. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group, 4991 Van Cutsem E. Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges editorial ; , 3325 van Daal WAJ, see van Tol-Geerdink JJ van Dam FSAM, see Schagen SB van de Velde H, see Dubois D van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PTR, Schimmel EC, Aleman BMP, van Leeuwen FE. LongTerm Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer, 467 Van den Bent MJ, see Mirimanoff R-O van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MCM, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial, 2715 van den Berg MP, see de Haas EC Van den Block L, Bilsen J, Deschepper R, Van Der Kelen G, Bernheim JL, Deliens L. End-of-Life Decisions Among Cancer Patients Compared With Noncancer Patients in Flanders, Belgium, 2842 van den Bout J, see van der Lee ML van der Bom JG, see van der Lee ML van der Does-van den Berg A, see te Loo DMWM Van der Graaf WTA, see De Bont ESJM van der Graaf WTA, see Perik PJ van der Holt B, see van Imhoff GW Van Der Kelen G, see Van den Block L van der Lee ML, van der Bom JG, Swarte NB, Heintz APM, de Graeff A, van den Bout J. In Reply correspondence ; , 3212 van der Putten H, see Madalinska JB and docusate.
Groups were 6.71 + 0.35, 8.1 + 1.00, and 9.9 + 0.75 * in groups I, II, and III, respectively. The FSH values for groups II and III were significantly higher than group 1, P 0.05. In the normal fertile men group l ; , a negative correlation existed between the baseline serum FSH and inhibin levels, r -0.415 P 0.005 ; Fig. 1 ; . In group I a negative correlation was also observed between the serum FSH response to GnRH and the basal serum inhibin levels, r -0.422 P 0.005 ; Fig. 2 ; . Furthermore, in group I serum inhibin levels were positively correlated with the geometric mean sperm count, r 0.35 P 0.01 ; Fig. 3 ; as well as testicular volume r 0.260 P 0.05 ; Fig. 4 ; . In contrast, no relationship between LH or T and inhibin levels existed in any of the three study groups. Serum T levels were 20.4 + 0.66, 18.7 + 0.90, and 20.4 f 1.18 nM L ~SEM ; in groups I, II, and III, respectively. These values were not different from each other. No correlations were detected in the analysis of the data from the two groups of men with a varicocele groups II and III ; as existed with the normal group of men for serum inhibin levels and either basal or GnRH-stimulated FSH levels, sperm count, or testicular volume data not shown.

Van Praagh I, Cure H, Leduc B et al. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate VEM ; as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist 2002; 7: 418 Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breastconservation rate. Br J Cancer 2003; 88: 1339 and dofetilide. Fig 1. Patient survival Kaplan-Meier estimate of survival of patients treated with docetaxel gemcitabine DG ; and vinorelbine cisplatinum VC ; regimens. There was no better effect with a higher dose of estramustine with docetaxel than for a lower dose and dok.

TABLE 3. Patients With Two Defibrillation Threshold Tests!

Based on this pooled efficacy analysis, trastuzumab vinorelbine based on 5 trials in a total of 178 patients ; and trastuzumab docetaxel cisplatin based on 1 study in 62 patients ; have the highest orrs for first-line therapy of mbc.
The main objective of our retrospective study was to evaluate the incidence of reversible chemotherapy-induced amenorrhea in patients treated with 6FEC and 3FEC 3D impact of sequential docetaxel on the rate of chemotherapy-related amenorrhea ; . Reversible amenorrhea was defined as recovery of regular menses and, where available 101 patients ; , premenopausal LH, FSH and 17-beta-estradiol values in the year following the last chemotherapy infusion. Premenopausal hormone concentrations were defined by our and doxorubicin. 1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 11821186, 1971. Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol., 20: 3906 3927, Kolata, G. Hope in the Lab: A Special Report--A Cautious Awe Greets Drugs that Eradicate Tumors in Mice. New York Times, May 3, 1998. 4. Twombly, R. First clinical trials of endostatin yield lukewarm results. J. Natl. Cancer Inst. Bethesda ; , 20: 1520 1521, Herbst, R. S., Hess, K. R., and Tran, H. T. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 20: 37923803, 2002. Thomas, J. P., Arzoomarian, R. Z., Alberti, D., Marnocha, R., Lee, F., and Friedl, A., et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patents with advanced solid tumors. J. Clin. Oncol., 21: 223231, 2003. Miller, K. D., Sweeney, C. J, and Sledge, G. W., Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol., 19: 1195 1206, Hotchkiss, K. A., Ashton, A. W., Mahmood, R., Russell, R. G., Sparano, J. A., and Schwartz, E. L. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel Taxotere ; is associated with impaired repositioning of the mictrotubule organizing center. Mol. Cancer Ther., 1: 11911200, 2002. Jain, R. K. Molecular regulation of vessel maturation. Nat. Med., 9: 685 693, Kerbel, R., and Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 10: 727739, 2002. Fernando, N. H., Hurwitz, H. I. Inhibition of vascular endothelial growth factor in the treatment of colon cancer. Semin. Oncol., 30 Suppl. 6 ; : 39 50, 2003. Saltz, L. B., Cox, J. V., Blanke, C., Rosen L. S., Fehrenbacker, L., Moore, M. S., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905914, 2000. Miller, K. D., Rugo, H. S., Cobleigh, M. A., Marcom, P. K., Chap, L. I., Holmes, F. A., et al. Phase III trial of capecitabine Xeloda ; plus.
We thank Julie Hoyt, Raywin Huang, Scott Barnhill, Luis Alvarado, and Serge Putvinski for their research contributions; Suzann Hahs for editorial assistance; and Miriam Weyer for graphics assistance. Received October 13, 2004. Accepted December 14, 2004. Address all correspondence and requests for reprints to: Andrew A. Young, M.D., Ph.D., Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, Suite 110, San Diego, California 92121. E-mail: ayoung amylin. com. This work was supported by Amylin Pharmaceuticals, Inc. San Diego, California ; . All authors are employees of Amylin Pharmaceuticals, Inc. and hold stock and or stock options in the company and dronabinol and docetaxel. However, if in looking back you say to yourself, "This wasn't all that bad a day. In fact, it was a really good day, " then I'd extend the practice of keeping a clear conscience into Monday as well. This study compared docetaxel with vinorelbine in enhancing surival in post-operative early breast cancer. An enhanced survival benefit has recently been found with the use of the monoclonal antibody trastuzumab, targeted against the amplified HER2 neu ErbB2 ; gene, in the adjuvant management of breast cancer. Its cardiotoxicity, particularly when combined with a taxane, raises some concern however. The investigators, therefore, assigned 1, 010 women with early breast cancer to receive either three cycles of docetaxel or vinorelbine. Both groups then received three cycles of fluorouracil, epirubicin and cyclophosphamide FEC ; . Tumours with amplified HER2 neu gene n 232 ; were further allocated to receive nine weekly trastuzumab infusions or not. Appropriate inclusion, exclusion and ethical considerations were applied. During the study, appropriate dose modifications and evaluations of toxicity were performed. The primary end point was recurrence-free survival. Secondary end points addressed adverse effects, cardiac ejection fraction, time to distant recurrence and and dss.
Either GHRH Ferring Pharmaceuticals Ltd., Hoofddorp, The Netherlands ; or GHRP-6 CLINALFA AG, Laufelingen, Switzerland ; was administered as an iv bolus injection of 1 g BW. Blood samples were drawn every 15 min from 15 to 120 min after injection. In the cross-over study, tests were performed in random order.

Platin VC ; in untreated advanced non-small-cell lung cancer NSCLC ; : A Southwest Oncology Group SWOG ; Trial. Proc ASCO1999: 18: A1777 Steward WP, Dunlop DJ, Dabouis G et al. Phase I I I study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results. Semin Oncol 1996; 23 Suppl 10 ; : S43-S47. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303. Abratt RP, Bezwoda WR, Goedhals L et al. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-9. Castellano D, Lianes P, Paz-Ares L et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 1998; 9: 457-9. Lippe P, Tummarello D, Monterubbianesi MC et al. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. Ann Oncol 1999; 10: 217-21. Anton A, Diaz Fernandez N, Gonzalez Larriba JL, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small-cell lung cancer NSCLC ; . Lung Cancer 1998; 22: 139-48. Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 1999; 17: 12-8 Sandier AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-30. Gatzemeier U, Rosell R, Betticher D et al. Randomized PanEuropean trial comparing paclitaxel TAX ; -carboplatin CAR ; versus paclitaxel-cisplatin CIS ; in advanced non-small-cell lung cancer NSCLC ; . Eur J Cancer 1999; 35 Suppl 4 ; : Abstr 973. Bonomi P, Kim KM, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-31. Manegold C. Bergman B, Chemaissani A et al. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-smallcell lung cancer. Ann Oncol 1997; 8: 525-9. Frasci G, Lorusso V. Panza N et al. Gemcitabine + vinorelbine GV ; yields better survival than vinorelbine V ; alone in elderly non-small cell lung cancer NSCLC ; patients. Final analysis of a Southern Italy Cooperative Oncology Group SICOG ; phase III trial. Proc ASCO 2000; 19: A1895. Georgoulias V, Papadakis E, Alexopoulos A et al. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multi-centre randomized phase II trial. Eur J Cancer 1999; 35 Suppl 4 ; : Abstr 986. Cornelia P, Frasci G, Panza N et al. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999, 17: 1526-34. Ginopoulos P, Mastronikolis NS, Giannios J et al. A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage Illb-IV non-small-cell lung cancer NSCLC ; . Lung Cancer 1999; 23: 31-7. Fig. 2. Expression analysis of docetaxel treated tumors. A, hierarchical cluster of tumors based on the expression of all genes passing initial filtering n 2, 271 ; . Treated cancers Rx ; do not cleanly separate from untreated cancers. B, heat map of the 332 genes with significant differential expression between untreated and treated prostate cancers. Mean normalized gene expression; red, high expression; blue, low expression. C, gene set enrichment analysis pathway results for the top 15 pathways ranked according to their normalized enrichment score * , P 0.05 ; . D, gene set enrichment analysis result for genes included in the ``androgen and estrogen metabolism'' pathway. The running score red line ; is based on the distribution of the genes blue lines ; after all genes n 22, 275 ; were ranked based on a signal-to-noise metric measuring the differential expression between treated and untreated cancers with those genes with increased expression in the treated tumors ranked at the top and those genes with decreased expression in the treated tumors ranked at the bottom. E, percent change in mean expression F SD ; for each gene in treated cancers when compared with untreated cancers ordered according to their signal-to-noise rank and represented as the percent of the untreated mean. Gene symbols and metabolic effects on bioactive androgens [increase red ; or decrease blue ; ] are provided.

Because medullary cavity was frequently undetectable. In those regions where radial and ulnar moments of inertia Iml, Iap and Ip ; were significantly different, toy group's values were significantly lower with respect to the other two groups. DISCUSSION Statistic analysis of the adimensional values showed that smaller bones are not an exact reduction of larger bones highlighting which parameters are significantly different and allowing mechanical speculations. Breed selection should have accidentally changed antebrachial three-dimensional ratios so that radius of toy breed dogs seems to be generally overstressed. Decrease of the medullary cavity in toy dogs may be an answer to continuous general overload leading to an increase of the CSA and, relatively, of the moments of inertia. From a pure geometrical point of view, considering disjointedly the two bones, these findings means that even if those bones in smaller dogs are adequately arranged to compressive loads they are less competent for axial bending. The very complex biomechanical situation of the entire antebrachium, due to the combined contribute of different variables, suggests anyway to deeply inquiring them all before a complete summary of the situation is reached and docusate.